151 related articles for article (PubMed ID: 14642622)
1. Dynamics of plasma hepatitis B virus levels after highly active antiretroviral therapy in patients with HIV infection.
Fang CT; Chen PJ; Chen MY; Hung CC; Chang SC; Chang AL; Chen DS
J Hepatol; 2003 Dec; 39(6):1028-35. PubMed ID: 14642622
[TBL] [Abstract][Full Text] [Related]
2. Impact of highly active antiretroviral therapy (HAART) on the natural history of hepatitis B virus (HBV) and HIV coinfection: relationship between prolonged efficacy of HAART and HBV surface and early antigen seroconversion.
Miailhes P; Trabaud MA; Pradat P; Lebouché B; Chevallier M; Chevallier P; Zoulim F; Trepo C
Clin Infect Dis; 2007 Sep; 45(5):624-32. PubMed ID: 17682999
[TBL] [Abstract][Full Text] [Related]
3. Virological outcome of chronic hepatitis B virus infection in HIV-coinfected patients receiving anti-HBV active antiretroviral therapy.
Núñez M; Ramos B; Díaz-Pollán B; Camino N; Martín-Carbonero L; Barreiro P; González-Lahoz J; Soriano V
AIDS Res Hum Retroviruses; 2006 Sep; 22(9):842-8. PubMed ID: 16989608
[TBL] [Abstract][Full Text] [Related]
4. [Patients co-infected with HIV and hepatitis-B virus (HBV): the favourable effect of lamivudine, as part of combined antiretroviral therapy, on HBV may be dependent upon the number of CD4-cells].
Smit MC; Haverkamp MH; Weersink AJ; Boucher CA; Hoepelman IM
Ned Tijdschr Geneeskd; 2004 Nov; 148(47):2330-4. PubMed ID: 15587052
[TBL] [Abstract][Full Text] [Related]
5. Differential clinical and virologic impact of hepatitis B virus genotypes B and C on HIV-coinfected patients receiving lamivudine-containing highly active antiretroviral therapy.
Sheng WH; Hung CC; Chang SY; Liu CJ; Chen MY; Hsieh SM; Kao JH; Chen PJ; Chang SC
Clin Infect Dis; 2012 Feb; 54(4):548-55. PubMed ID: 22156858
[TBL] [Abstract][Full Text] [Related]
6. Five-year on-treatment efficacy of lamivudine-, tenofovir- and tenofovir + emtricitabine-based HAART in HBV-HIV-coinfected patients.
Kosi L; Reiberger T; Payer BA; Grabmeier-Pfistershammer K; Strassl R; Rieger A; Peck-Radosavljevic M
J Viral Hepat; 2012 Nov; 19(11):801-10. PubMed ID: 23043387
[TBL] [Abstract][Full Text] [Related]
7. Impact of tenofovir-containing antiretroviral therapy on chronic hepatitis B in a cohort co-infected with human immunodeficiency virus.
Stephan C; Berger A; Carlebach A; Lutz T; Bickel M; Klauke S; Staszewski S; Stuermer M
J Antimicrob Chemother; 2005 Dec; 56(6):1087-93. PubMed ID: 16269552
[TBL] [Abstract][Full Text] [Related]
8. Predictors of HBeAg status and hepatitis B viraemia in HIV-infected patients with chronic hepatitis B in the HAART era in Brazil.
Mendes-Correa MC; Pinho JR; Gomes-Gouvea MS; da Silva AC; Guastini CF; Martins LG; Leite AG; Silva MH; Gianini RJ; Uip DE
BMC Infect Dis; 2011 Sep; 11():247. PubMed ID: 21933423
[TBL] [Abstract][Full Text] [Related]
9. Persistent viremia in human immunodeficiency virus/hepatitis B coinfected patients undergoing long-term tenofovir: virological and clinical implications.
Boyd A; Gozlan J; Maylin S; Delaugerre C; Peytavin G; Girard PM; Zoulim F; Lacombe K
Hepatology; 2014 Aug; 60(2):497-507. PubMed ID: 24752996
[TBL] [Abstract][Full Text] [Related]
10. Occult hepatitis B virus infection before and 1 year after start of HAART in HIV type 1-positive patients.
Pogány K; Zaaijer HL; Prins JM; Wit FW; Lange JM; Beld MG
AIDS Res Hum Retroviruses; 2005 Nov; 21(11):922-6. PubMed ID: 16386107
[TBL] [Abstract][Full Text] [Related]
11. Long-term hepatitis B virus (HBV) response to lamivudine-containing highly active antiretroviral therapy in HIV-HBV co-infected patients in Thailand.
Khamduang W; Gaudy-Graffin C; Ngo-Giang-Huong N; Jourdain G; Moreau A; Luekamlung N; Halue G; Buranawanitchakorn Y; Kunkongkapan S; Buranabanjasatean S; Lallemant M; Sirirungsi W; Goudeau A;
PLoS One; 2012; 7(7):e42184. PubMed ID: 22860080
[TBL] [Abstract][Full Text] [Related]
12. Long-term hepatitis B virus dynamics in HIV-hepatitis B virus-co-infected patients treated with tenofovir disoproxil fumarate.
Lacombe K; Gozlan J; Boelle PY; Serfaty L; Zoulim F; Valleron AJ; Girard PM
AIDS; 2005 Jun; 19(9):907-15. PubMed ID: 15905671
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of entecavir for chronic HBV in HIV/HBV coinfected patients receiving lamivudine as part of antiretroviral therapy.
Pessôa MG; Gazzard B; Huang AK; Brandão-Mello CE; Cassetti I; Mendes-Corrêa MC; Soriano V; Phiri P; Hall A; Brett-Smith H
AIDS; 2008 Sep; 22(14):1779-87. PubMed ID: 18753861
[TBL] [Abstract][Full Text] [Related]
14. Frequent occurrence of chronic hepatitis B virus infection among West African HIV type-1-infected children.
Rouet F; Chaix ML; Inwoley A; Anaky MF; Fassinou P; Kpozehouen A; Rouzioux C; Blanche S; Msellati P;
Clin Infect Dis; 2008 Feb; 46(3):361-6. PubMed ID: 18171303
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis B virus variants in an HIV-HBV co-infected patient at different periods of antiretroviral treatment with and without lamivudine.
Santos EA; Sucupira MV; Arabe J; Gomes SA
BMC Infect Dis; 2004 Aug; 4():29. PubMed ID: 15339340
[TBL] [Abstract][Full Text] [Related]
16. HBV lamivudine resistance among hepatitis B and HIV coinfected patients starting lamivudine, stavudine and nevirapine in Kenya.
Kim HN; Scott J; Cent A; Cook L; Morrow RA; Richardson B; Tapia K; Jerome KR; Lule G; John-Stewart G; Chung MH
J Viral Hepat; 2011 Oct; 18(10):e447-52. PubMed ID: 21914062
[TBL] [Abstract][Full Text] [Related]
17. Evidence of susceptibility to lamivudine-based HAART and genetic stability of hepatitis B virus (HBV) in HIV co-infected patients: A South African longitudinal HBV whole genome study.
Amponsah-Dacosta E; Rakgole JN; Gededzha MP; Lukhwareni A; Blackard JT; Selabe SG; Mphahlele MJ
Infect Genet Evol; 2016 Sep; 43():232-8. PubMed ID: 27245151
[TBL] [Abstract][Full Text] [Related]
18. High incidence of lamivudine-resistance-associated vaccine-escape HBV mutants among HIV-coinfected patients on prolonged antiretroviral therapy.
Pal A; Sarkar N; Saha D; Guha SK; Saha B; Chakrabarti S; Chakravarty R
Antivir Ther; 2015; 20(5):545-54. PubMed ID: 25654813
[TBL] [Abstract][Full Text] [Related]
19. Hepatitis B virus genotypes and lamivudine resistance mutations in HIV/hepatitis B virus-coinfected patients.
Ramos B; Núñez M; Martín-Carbonero L; Sheldon J; Rios P; Labarga P; Romero M; Barreiro P; García-Samaniego J; Soriano V
J Acquir Immune Defic Syndr; 2007 Apr; 44(5):557-61. PubMed ID: 17224847
[TBL] [Abstract][Full Text] [Related]
20. Epidemiology of HBV infection in a cohort of Ugandan HIV-infected patients and rate and pattern of lamivudine-resistant HBV infection in patients receiving antiretroviral therapy.
Calisti G; Muhindo R; Boum Y; Wilson LA; Foster GM; Geretti AM; Bhagani S
Trans R Soc Trop Med Hyg; 2015 Nov; 109(11):723-9. PubMed ID: 26386408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
